Medical start-up Nanosynex was founded by CEO Diane Abensur and VP marketing and business development Michelle Heymann, who met when they were studying for MBAs at the Technion. Both had recently immigrated to Israel; Abensur from France and Heymann from Brazil.
Based on findings by renowned Technion-Israel Institute of Technology cell researcher Prof. Shulamit Levenberg, Nanosynex has developed a method of precisely adapting antibiotics to infections. The objective is to implement more effective and faster treatment without encouraging the resistance of bacteria to the most widely used antibiotics.